These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1443 related items for PubMed ID: 17158758

  • 1. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

  • 2. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
    Glaros S, Atanaskova N, Zhao C, Skafar DF, Reddy KB.
    Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
    [Abstract] [Full Text] [Related]

  • 3. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW.
    Oncogene; 2010 May 20; 29(20):2983-95. PubMed ID: 20208560
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.
    Breast Cancer Res Treat; 2010 Jul 20; 122(2):395-407. PubMed ID: 19847644
    [Abstract] [Full Text] [Related]

  • 6. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
    Lu M, Mira-y-Lopez R, Nakajo S, Nakaya K, Jing Y.
    Oncogene; 2005 Jun 23; 24(27):4362-9. PubMed ID: 15870697
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells.
    Lo R, Burgoon L, Macpherson L, Ahmed S, Matthews J.
    Biochim Biophys Acta; 2010 Jun 23; 1799(5-6):469-79. PubMed ID: 20079471
    [Abstract] [Full Text] [Related]

  • 11. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H.
    Breast Cancer Res; 2005 Jun 23; 7(5):R753-64. PubMed ID: 16168121
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.
    Weitsman GE, Weebadda W, Ung K, Murphy LC.
    Breast Cancer Res Treat; 2009 Nov 23; 118(2):269-79. PubMed ID: 18941890
    [Abstract] [Full Text] [Related]

  • 14. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
    Motomura K, Ishitobi M, Komoike Y, Koyama H, Nagase H, Inaji H, Noguchi S.
    Oncology; 2010 Nov 23; 79(1-2):55-61. PubMed ID: 21071990
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
    Al-Dhaheri MH, Rowan BG.
    Mol Endocrinol; 2007 Feb 23; 21(2):439-56. PubMed ID: 17068199
    [Abstract] [Full Text] [Related]

  • 18. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.
    J Natl Cancer Inst; 2011 Apr 06; 103(7):538-52. PubMed ID: 21447808
    [Abstract] [Full Text] [Related]

  • 19. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
    Anticancer Res; 2006 Apr 06; 26(3A):1773-84. PubMed ID: 16827106
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.